Literature DB >> 874470

The demonstration of a change in responsiveness of mice to physostigmine and atropine after withdrawal from long-term haloperidol pretreatment.

R Dunstan, D M Jackson.   

Abstract

Mice, administered haloperidol 3 mg/kg/day, in their drinking water for 21 days, were tested for their responsiveness to cholinergic and anticholinergic drugs 4 days after withdrawal from haloperidol (or vehicle). Haloperidol-treated animals administered methylhyoscine (1 mg/kg i.p.) and various doses of physostigmine (5 to 1215 microgram/kg) displayed significantly less depression of locomotor activity than vehicle-treated animals. Atropine, 5 mg/kg, whilst ineffective in producing locomotor stimulation in vehicle-treated animals, produced marked stimulation in haloperidol-treated animals. Methylatropine (5 mg/kg) did not produce significant stimulation in either group. Dopamine receptor supersensitivity was present in these animals as haloperidol-treated mice, pretreated with alpha-methyltyrosine and reserpine, displayed a significantly greater locomotor response to apomorphine than did vehicle-treated animals. The data support the hypothesis that long-term administration of haloperidol produces an apparent hyposensitivity of central muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874470     DOI: 10.1007/bf01300132

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  23 in total

1.  Augmentation of the behavioral effects of amphetamine by scopolamine.

Authors:  P L CARLTON
Journal:  Psychopharmacologia       Date:  1961

2.  Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment.

Authors:  P F Vonvoigtlander; E G Losey; H J Triezenberg
Journal:  J Pharmacol Exp Ther       Date:  1975-04       Impact factor: 4.030

3.  Alteration in the action of cholinergic and anti cholinergic drugs after chronic haloperidol: indirect evidence for cholinergic hyposensitivity.

Authors:  G Gianutsos; H Lal
Journal:  Life Sci       Date:  1976-03-01       Impact factor: 5.037

4.  The demonstration of a change in adrenergic receptor sensitivity in the central nervous system of mice after withdrawal from long-term treatment with haloperidol.

Authors:  R Dunstan; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

Review 5.  Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs.

Authors:  S H Snyder
Journal:  Biol Psychiatry       Date:  1970-10       Impact factor: 13.382

6.  The interaction between beta-phenylethylamine and agents which affect the cholinergic nervous system on locomotor activity and toxicity in mice.

Authors:  D M Jackson
Journal:  Arzneimittelforschung       Date:  1974-01

7.  Interactions between central cholinergic agents and amphetamine in mice.

Authors:  J H Mennear
Journal:  Psychopharmacologia       Date:  1965-02-15

8.  Effects of cholinolytic agents on behavior following development of tolerance to low cholinesterase activity.

Authors:  R W Russell; B J Vasquez; D H Overstreet; F W Dalglish
Journal:  Psychopharmacologia       Date:  1971

9.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

10.  The effect of apomorphine and clonidine on locomotor activity in mice after long term treatment with haloperidol.

Authors:  R Dunstan; D M Jackson
Journal:  Clin Exp Pharmacol Physiol       Date:  1977 Mar-Apr       Impact factor: 2.557

View more
  11 in total

1.  Long-term L-dopa pretreatment of mice: central receptor subsensitivity or supersensitivity?

Authors:  R C Bailey; D M Jackson; P U Bracs
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

Review 2.  Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

Authors:  P Muller; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

Review 3.  The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

Authors:  Jordy van Enkhuizen; David S Janowsky; Berend Olivier; Arpi Minassian; William Perry; Jared W Young; Mark A Geyer
Journal:  Eur J Pharmacol       Date:  2014-08-05       Impact factor: 4.432

4.  Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features.

Authors:  Jordy van Enkhuizen; Morgane Milienne-Petiot; Mark A Geyer; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

5.  Long-term haloperidol-treatment of mice: a change in beta-adrenergic receptor responsiveness.

Authors:  R Dunstan; D M Jackson
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

6.  Altered pilocarpine- or chlorpromazine-induced catalepsy after long-term treatment with cholinergic drugs.

Authors:  G Gianutsos
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

7.  Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation.

Authors:  S Tufik
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Chronic haloperidol and adrenergic receptor sensitivity in the rat.

Authors:  A Perrington; R Einstein; D M Jackson; M J Christie
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

9.  The hyperkinetic syndrome following long-term haloperidol treatment: involvement of dopamine and noradrenaline.

Authors:  D M Jackson; R Dunstan; A Perrington
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

10.  Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.

Authors:  K Yamada; T Furukawa
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.